Thoracic Malignancies

Breast Cancer

Questions discussed in this category

How do you manage anticoagulation for patients with DVT/PE who have brain metastases?

Some medical oncologists tend to hold anticoagulation in patients who develop brain metastases for fear of causing intracranial hemorrhage. Is there a...

4 Answers available

What are your top takeaways from ESMO 2023?

10 Answers available

How would you manage a left sided triple negative breast cancer with a concurrent left sided locally advanced non-small cell lung cancer?

The left breast cancer is an ER-negative, PR-negative, HER2-negative cT2N0 invasive ductal carcinoma, while the left lung primary is a cT2N1 squamous ...

4 Answers available

What are best practices for oncologists during the national platinum shortage?

Please specify how your institution is allocating resources now or will be soon.

13 Answers available

When do you refer patients for germline testing when somatic tumor testing is negative for actionable mutations?

How reliable is somatic testing to detect an underlying germline predisposition?

2 Answers available

How do you interpret efficacy of trastuzumab deruxtecan based on HER2 mutation type and/or level of HER2 overexpression?

How and when do you plan to perform HER2 testing in patients with NSCLC?

2 Answers available

Do you find data from phase 2 DESTINY-LUNG01 study sufficient to change practice in HER2 mutant NSCLC or is a phase 3 study still needed?

How does trastuzumab deruxtecan compare to other HER2 targeted strategies?

3 Answers available

What strategies can be employed to manage interstitial lung disease seen with trastuzumab deruxtecan?

Can patients be re-challenged after developing ILD? Is the toxicity seen with T-Dxd a potential barrier to use? Do you feel the dosing used in...

2 Answers available

Do you recommend a dose constraint for breast implants when treating a patient for NSCLC with radiotherapy?

In the case of conventional fractionation or SBRT, would you constrain the implants? (No history of breast cancer.)

1 Answer available

Should we be utilizing prophylactic G-CSF in our patients with intermediate risk of febrile neutropenia due to the COVID-19 pandemic?

Are you placing more weight on patient risk factors such as age >65 or co-morbidities?

2 Answers available

What scenarios, if any, are you delaying adjuvant chemotherapy in light of the COVID-19 outbreak?

1 Answer available

Do you recommend routine dental evaluation for all patients before starting bisphosponates in patients with bone metastases?

1 Answer available

How does your management change for patients with bone marrow failure due to a metastatic solid tumor to the marrow?

Do you offer EPO and TPO support? Do you modify your systemic therapy up front or after subsequent cycles?

1 Answer available

Should special precautions be taken when treating oligometastatic disease in the sacrum or pelvis with SBRT in a patient with a long life expectancy?

For example in a patient with a good performance status and a biologically favorable cancer (ER+ breast cancer, EGFR+ NSCLC, or prostate cancer), are ...

1 Answer available